Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

Detalles Bibliográficos
Autores principales: Wallace, Katrine, Goble, Sandra, Isaacson, Jeff, Maloney, Lara, Cameron, Terri, Bedel, Josh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830408/
https://www.ncbi.nlm.nih.gov/pubmed/31172449
http://dx.doi.org/10.1007/s40273-019-00815-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830408/
https://www.ncbi.nlm.nih.gov/pubmed/31172449
http://dx.doi.org/10.1007/s40273-019-00815-3

Ejemplares similares